BLAST demonstrates higher prognostic accuracy for survival than CPSS in Chinese patients with chronic myelomonocytic leukemia - Takeaways - MDSpire

BLAST demonstrates higher prognostic accuracy for survival than CPSS in Chinese patients with chronic myelomonocytic leukemia

  • By

  • Xin Yan

  • Gege Feng

  • Zhimei Cai

  • Jiale Ma

  • Shuqian Xu

  • Zheng Ge

  • June 17, 2026

  • 0 min

Share

  • 1

    Chronic myelomonocytic leukemia (CMML) shows significant variability in patient prognosis, necessitating effective risk stratification tools.

  • 2

    The BLAST and BLAST-mol models, developed by Tefferi et al., outperform existing prognostic tools like CPSS in predicting survival outcomes.

  • 3

    In a study of 125 Chinese CMML patients, BLAST identified 72% as high-risk, with a median overall survival of 14 months.

  • 4

    Severe anemia and TP53 mutations were identified as independent poor prognostic factors for overall survival in multivariable analysis.

  • 5

    The CPSS-mol model showed limited discrimination between intermediate-2 and high-risk groups, indicating a need for improved stratification.

Original Source(s)

BLAST demonstrates higher prognostic accuracy for survival than CPSS in Chinese patients with chronic myelomonocytic leukemia

  • by Xin Yan, Gege Feng, Zhimei Cai, Jiale Ma, Shuqian Xu, Zheng Ge

  • June 17, 2026

Related Content

A Family at War—Against Tropheryma whipplei: A Case Series

The impact of anemia and blood transfusion on mortality after open abdominal surgery in the elderly

Toni Choueiri, MD discusses a novel HIF-2alpha inhibitor called casdatifan

Results show it was well-tolerated and showed promising early clinical activity in heavily pretreated patients with clear cell renal cell carcinoma. 

  • February 26, 2025

  • 1 min